B. Riley decreased their FY2024 earnings estimates for Novavax in a report issued on Thursday, February 20th. B. Riley ...

Novavax NVAX is expected to report fourth-quarter and full-year 2024 earnings later this month. In the last reported quarter, ...

Stocks of MRNA, PFE, NVAX and BNTX rose in anticipation that a new virus in China could trigger another pandemic.

Unusual total active option classes on open include: Opko Health ( OPK ), Chewy ( CHWY ), Mini SPX (.XSP), EFA (EFA), Novavax ( NVAX ), B Riley Financial ( RILY ), Pinduoduo ( PDD ), Lucid Group ( ...

Bullish option flow detected in Novavax (NVAX) with 23,789 calls trading, 3x expected, and implied vol increasing over 8 points to 114.25%.

CoV-2, which can enter human cells using the same gateway as the highly contagious SAR-CoV-2 virus that causes COVID-19.

Novavax NVAX is expected to report fourth-quarter and full-year 2024 earnings later this month. In the last reported quarter, the company’s earnings beat estimates by 12.64%. The Zacks Consensus ...

Virologists warn the pathogen should be monitored ‘very, very carefully’ because it attacks human cells in the same way as ...

Novavax (NVAX) ended the recent trading session at $7.92, demonstrating a -1.25% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 0.43%.

Shares of Novavax Inc. NVAX slipped 1.25% to $7.92 Thursday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.47% to 19,962.

The stock's fall snapped a three-day winning streak.